In melanoma patients harboring BRAF-V600 mutations, a combination of Dabrafenib with the allosteric MEK inhibitor Trametinib has been shown to improve overall survival and decrease the risk of adverse events related to paradoxical ERK activation when compared to Vemurafenib and Dabrafenib monotherapy, although ultimately combined therapy also ends with resistance [22–24, 27, 29, 31, 32]. This evidence concerns the gene MAP2K7 and melanoma.